Temiz MZ, Cakir OO, Aykan S, Kucuk SH, Tiryakioglu NO, Bilek G, Tunali NE, Kandirali E, Semercioz A. The use of serum zinc to prostate-specific antigen ratio as a biomarker in the prediction of prostate biopsy outcomes.
Biomark Med 2019;
13:59-68. [PMID:
30672309 DOI:
10.2217/bmm-2018-0260]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
AIM
To generate a combination of serum zinc (Zn) and prostate-specific antigen (PSA) in an attempt to provide better prediction of prostate biopsy outcomes with Zn/PSA ratios.
MATERIALS & METHODS
Diagnostic performances of PSA and Zn/PSA were investigated using receiver operating characteristic and the area under the curve analysis and McNemar test in 480 men. Decision curve analysis was also used to determine the net clinical benefits of the two parameters.
RESULTS
The receiver operating characteristic-area under the curve analysis established a similar diagnostic performance for both parameters. Although Zn/PSA had a higher diagnostic sensitivity, PSA was superior in terms of specificity and net clinical benefits.
CONCLUSION
Zn/PSA has no substantial superiority in the prediction of prostate biopsy outcomes.
Collapse